<DOC>
	<DOCNO>NCT01837043</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy conversion calcineurin inhibitor ( tacrolimus cyclosporine ) immunosuppression therapy NulojixÂ® ( belatacept ) immunosuppression therapy patient delay ( DGF ) slow graft function ( SGF ) follow kidney transplantation . Patients risk SGF DGF consent time kidney transplantation . On post-op Day 5 patient assess , develop SGF DGF randomize convert Belatacept continue CNI regimen . Up 20 subject develop DGF follow control subject . Seventy randomize subject follow total 14 month renal biopsy Month 12 post transplant . Research Hypotheses : Primary Hypotheses : - Kidneys slow delay graft function susceptible acute long-term CNI toxicity - Kidneys convert calcineurin inhibitor base therapy belatacept achieve rapid recovery post-ischemic acute tubular necrosis ( ATN ) improve 1 year calculate GFR . Key Secondary Hypotheses : - Renal Histology : Belatacept convert patient low chronic allograft damage index ( CADI ) score low interstitial fibrosis tubular atrophy ( IF/TA ) score calculate Banff criterion 1 year post- transplant - Biomarker Analysis : Biomarker analysis ( clusterin ) measure serial urine collection 1 ) directly assess CNI induce kidney injury 2 ) improve prediction patient benefit early belatacept conversion .</brief_summary>
	<brief_title>Early Conversion From CNI Belatacept Renal Transplant Recipients With Delayed Slow Graft Function</brief_title>
	<detailed_description />
	<mesh_term>Delayed Graft Function</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Before study procedure perform , subject detail study describe , give write informed consent document read . Then , subject consent participate study , indicate consent sign date informed consent document presence study personnel . All patient ( &gt; 18 year ) receive deceased donor transplant risk SGF/DGF study All gender ethnicity consider study At risk SGF/DGF define : ECD ( Extended Criteria Donor ) donor kidney recipient ECD define donor age 60 age 50 60 2 follow risk factor : Terminal creatinine &gt; 1.5 mg/dL History Hypertension Death due cerebrovascular accident Donations cardiac death ( DCD ) kidney recipient Donor organs actual cold ischemia time ( CIT ) &gt; 19 hour Recipients donor organ terminal creatinine &gt; 1.5 mg/dL Only patient receive Thymoglobulin induction CNI maintenance time randomization consider study Men woman , 18 70 year age Reproductive status : Definition Women ChildBearing Potential ( WOCBP ) . WOCBP comprise woman experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : Women amenorrhea &gt; = 12 consecutive month ( without another cause ) document serum folliclestimulating hormone ( FSH ) level &gt; 35 mIU/mL Women irregular menstrual period document serum FSH level &gt; 35 mIU/mL Women take hormone replacement therapy The following WOCBP : Women use follow method prevent pregnancy : oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) . Women practice abstinence Women partner sterile ( due vasectomy ) WOCBP must use acceptable method contraception avoid pregnancy throughout study 8 week last dose study drug manner risk pregnancy minimize WOCBP must negative serum urine pregnancy test result ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour first dose study drug . Women must breastfeed Sexually active fertile men must use effective birth control partner WOCBP Seronegative unknown EBV ( Epstein Barr Virus ) serostatus ( due risk posttransplant lymphoproliferative disorder , PTLD ) predominantly involve central nervous system Patients tuberculosis treat latent infection Patients high risk polyoma virusassociated nephropathy , mostly due BK virus infection Rejection episode randomization Anatomic cause SGF/DGF urinary leak , obstruction thrombosis Patients prior concurrent nonrenal solid organ transplant Patients live donor kidney Patients pediatric kidney ( age le 5 year ) Dual kidney transplant ( donor ) Immunologically high risk patient positive crossmatch pre transplantation donor specific antibody ( DSA ) &gt; 5000 MFI ABO Incompatible transplantation Patients HIV Subjects active infection contraindication would normally exclude transplantation Patients history malignancy last 5 year except non melanoma skin cancer Baseline white blood cell count le 2,000 Baseline hemoglobin le 8 g/dL Patients prior allergic reaction belatacept Patients prior allergic reaction thymoglobulin Sex Reproductive status see WOCBP information inclusion Subjects currently receive immunosuppressive agent ( ) indication autoimmune disease subject comorbidities treatment agent likely trial . Subjects use investigational drug within 30 day prior Day 1 visit Subjects previously treat belatacept Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( e.g . infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Delayed Graft Function</keyword>
	<keyword>Renal Transplantation</keyword>
	<keyword>Kidney Transplant</keyword>
</DOC>